ATTENDANCE

List Committee Members          WADA Staff
Pr. Ken Fitch (Acting Chairman)  Mr. Richard Pound
Dr. Andrew Pipe                   Mr. David Howman
Dr. George Ruijsch van Dugteren   Mr. Olivier Niggli
Pr. Klaus Mueller                 Dr. Olivier Rabin
Pr. Harm Kuipers                  Mr. Casey Wade
Mr. Philippe Verbiest             Dr. Alain Garnier
Dr. Eduardo Henrique de Rose      Ms. Jennifer Ebermann
Dr. Gary Wadler                   Ms. Danielle Nethercott

Apologies
Pr. Arne Ljungqvist (Chairman)
Pr. Jordi Segura

Welcome

Mr. Pound opens the meeting by first welcoming and thanking everyone for their hard voluntary work and the scientific collegiality that they will bring to the process. He reiterates the importance of the task at hand; to extrapolate a sound and credible List of Prohibited Substances and Methods, ultimately to be guided by the international scientific expertise embodied in List Committee. He wishes for a scientific consensus and expects solidarity on the decisions made.

He also explains Mr. Howman’s and Mr. Niggli’s role in this meeting; making sure that the List maintains Code compliance from a legal standpoint.

Confidentiality is of extreme importance in this process.

Mr. Howman also takes the opportunity to express his thanks to the group in knowing that they will provide the quality of science required for this important process. He mentions that the WADA List of Prohibited Substances represents very important work and that it is one of the cornerstones of the World Anti-Doping Code; without a List there is no Code.
The Acting Chair thanks Mr. Pound, Mr. Howman and everyone involved in this important process. He also explains how he will be performing the duties of acting chair for his esteemed colleague, Prof Arne Ljungqvist.

The Chair reminds everyone that the WADA List Committee and TUE Committee are sub-committees to the HMR Committee. As a result, all changes brought forth by the List Committee will have to be reviewed and approved by the HMR Committee prior to submission to the EXCO.

**Purpose of Meeting**

Ultimately, the purpose of the meeting is for the List Committee to:

1. Review and consider all the feedback brought forth in the consultation process with our main stakeholders
2. Propose changes/update to the List that are founded on sound scientific basis
3. Make sure that proposed changes comply with the WADC
4. Finalize the proposed List to be presented to the Executive Committee for acceptance (effective January 1, 2004)

The revision and updates brought forth by the List Committee during the course of this meeting will be submitted to the Executive Committee on September 23, 2003. Acceptance of the latter will mean that the WADA 2004 List of Prohibited Substances and Methods will come into effect as of January 1st, 2004 and in full force during for the Summer Olympic Games in Athens, Greece.

Mr. Wade explains the specific roles and responsibilities that each WADA staff has;

- Olivier Niggli & David Howman: Legal Compliance of the List with the Code
- Dr. Olivier Rabin & Dr. Alain Garnier: In-house scientific and technical expertise
- Casey Wade: Facilitator
- Jennifer Ebermann: Administration; Document Control
- Danielle Nethercott: Administration; General

**Review of Agenda**

Mr. Wade explains to the Members that the agenda applies to the two day period and that no time frames have been specifically allocated to the agenda items. An open-ended agenda will give the Acting Chair and List Committee full flexibility in choosing and adopting the optimal review process.

Mr. Wade also provides an orientation of all the documents presented in the meeting binders; The Consultation Package Documents, Stakeholder feedback compiled and sorted by substance and supportive scientific documentation.
Update on WADC & Doping Control Program & Doping Control Program

Mr. Wade explains that the World Anti Doping Code (WADC) was adopted at the Conference in Copenhagen; to be effective January 1 2004. The timelines being 2004 Athens Summer Olympic Games for the Sports Movement and 2006 Torino Winter Olympic Games for the Governments. Linked to the WADC are four mandatory standards being: Laboratory, Testing, Therapeutic Use Exemptions (TUE) and the List of Prohibited Substance and Methods.

The Models of Best Practice are there to assist organizations to comply with the World Anti-Doping Code

Process for Review and Modification

Prior to the meeting, each member of the List Working Group was asked by our Acting Chair to summarize the feedback received on specific substance(s).

The Chair suggests that we go through the draft List Standard document one section/substance at a time. Each member will present a summary of their respective substance to lead the List Committee into a discussion and eventually to a subsequent decision.

The group mentions several times that an Explanatory document should be created to explain the rationalization behind the decisions to remove substances.
SUBSTANCES & METHODS PROHIBITED IN COMPETITION

S1 – Stimulants
Prof Klaus Mueller provides the List Committee Members with a summary on the feedback received on ‘S1 – Stimulants’.

Decisions:

1. Added the text “where relevant”
2. Added Adrafinil in the List of substances
3. Deleted “s” from the word “amphetamine” to depict a specific drug versus a category.
   1. Removed “dexamphetamine” and “levmethamphetamine” and inserted “methylamphetamine”.
   2. Remove caffeine and pseudoephedrine from the List and place it on the Monitoring Program.

S2 – Beta-2-Agonists

Decision

1. “S2 - Beta 2 Agonists” as a section is deleted in its entirety from this location in the document (Refer to newly created “S6 – Beta 2 Agonists” in the new version). It was felt that Beta-2-Agonists should be referenced in only one section in the standard and not two sections as it currently stand now (refer to the Anabolic agents’; decision to remove point two on Beta 2 Agonists).

2. Wording for the Beta 2 Agonist Section was drafted and agreed by the Committee.

This section now figures as “S6 - Beta-2 Agonists” in the draft List Standard, version 3.
**S3 – Narcotics**

Dr. Gary Wadler summarizes the feedback received from the consultation process. Generally the feedback indicates that we should maintain Narcotics.

<table>
<thead>
<tr>
<th>Decisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Oxymorphone is added to the List</td>
</tr>
<tr>
<td>2. Morphine is prohibited</td>
</tr>
</tbody>
</table>

**S4 – Cannabinoids**

Dr. Andrew Pipe provides an overview of the feedback.

<table>
<thead>
<tr>
<th>Decision</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. All cannabinoids are prohibited</td>
</tr>
</tbody>
</table>

**S5 - Anabolic Agents**

Dr. Gary Wadler presents an overview for this class of substances;

<table>
<thead>
<tr>
<th>Decisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Addition of the substances 'boldione' and '4-hydroxy-19-nortestosterone'</td>
</tr>
<tr>
<td>2. Removal of section, &quot;2. Beta-2-Agonists with anabolic properties&quot; is deleted from this substance category.</td>
</tr>
<tr>
<td>3. Wording surrounding the explanatory text was slightly amended.</td>
</tr>
<tr>
<td>♦ Took out “based on any reliable analysis method” (p.11).</td>
</tr>
<tr>
<td>♦ Deleted the word “even” starting the next paragraph (p.11).</td>
</tr>
<tr>
<td>♦ Amended text to become “at least three times within a 3 month period.”</td>
</tr>
</tbody>
</table>

**S6 – Peptide Hormones**

Prof. Klaus Mueller summarizes the situation for this class of substances.

<table>
<thead>
<tr>
<th>Decision</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. The group unanimously agrees to revisit corticotrophins in conjunction with glucocorticosteroids discussion.</td>
</tr>
</tbody>
</table>
**S7 – Agents with Anti-Oestrogenic Activity**

Decision

No changes are made to this section.

**S8 – Masking Agents**

The Chair reviews the situation.

**Decisions**

1. Added ‘dextrans’ as a plasma expander in this substance category.
2. Rewording of the definition that pertains to “Diuretics”

**M1 – Enhancement of Oxygen Transfer**

The Chair summarizes the background information.

**Decisions**

The group votes to remove the wording “justified by a TUE” and otherwise leave this category as is.

**M2 – Pharmacological, Chemical & Physical Manipulation**

**Decision**

The group agrees that this category should remain as is with the exception of the replacing the word “measurements” with “concentrations” for clarity purposes.

**M3 – Gene Doping**

**Decision**

The group agrees that no changes are necessary for this group.

**Substances & Methods Prohibited In and Out of Competition**

This section remains as is.
Substances & Methods Prohibited In Particular Sports

Specified Substances

The following decisions were made by the group:

**STIMULULANTS**

1. General consensus – remove word “all” in front of “Stimulants”
2. Levmethamphetamine – change to “L-methylamphetamine”...lessens confusion and is more in agreement with the previous changes that directly implying that it belongs to L-isomers

**NARCOTICS**

Whole section deleted; removed the category and description completely

**DIURETICS**

Removed the word “all” preceding “diuretics”

**MASKING AGENTS**

Consensus is to leave as is.

**BETA BLOCKERS**

Decision; remove “beta-blockers” and leave “unless the IF decides otherwise”

**ALCOHOL**

Decision; add “unless the IF decides otherwise”

**CANNABINOIDS**

Leave as is

**GLUCOCORTICOSTEROIDS**

Point will be re-addressed with the HM&R Committee

**MONITORING PROGRAM**

The following points and discussions are brought up by the group;
♦ It is agreed by that the, “The nature, scope and duration of monitoring will be determined by WADA”.

♦ The Monitoring Program will be published simultaneously with the List so that all athletes are informed.

♦ Labs will be more comfortable if there is a time limit on substances being monitored (due to cost implications) for reporting purposes.

Suggest keeping monitoring program as general as possible and more specific information to the technical document of the Laboratory Standard.

**Alcohol**
Testing responsibilities will be left to the International Sport Federations (ISF) or Anti-Doping Agencies (ADOs). Breath analysis is recommended.

It will be the responsibility of WADA management to confirm which ISFs wish to ban alcohol and define reporting thresholds.

**Beta-Blockers**
There were some doubtful responses in the feedback received during the consultation process, therefore it is felt that responses need to be revisited. As a result, WADA management will contact the ISFs to confirm their wish to ban beta-blockers and provide an update as soon as possible.

**Diuretics**

The List Committee agrees that that there is a need to identify those sports with weight categories where diuretics need to be banned (no TUEs acceptable) as performance enhancing substances. WADA Management will follow-up with the ISF and update accordingly.